Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.

ABSTRACT:

Background

Previous studies on the role of TP53 mutation in breast cancer treatment response and survival are contradictory and inconclusive, limited by the use of different endpoints to determine clinical significance and by small sample sizes that prohibit stratification by treatment.

Methods

We utilized large datasets to examine overall survival according to TP53 mutation status in patients across multiple clinical features and treatments.

Results

Confirming other studies, we found that in all patients and in hormone therapy-treated patients, TP53 wild-type status conferred superior 5-year overall survival, but survival curves crossed at 10 or more years. In contrast, further stratification within the large dataset revealed that in patients receiving chemotherapy a

SUBMITTER: Ungerleider NA 

PROVIDER: S-EPMC6167800 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature